Cemiplimab plus peltopepimut-S vaccine in recurrent cervical cancer: A phase 2 clinical trial

Domenica Lorusso*, Ana Oaknin, Giuliano S. Borges, Fernanda Damian, Nelleke Ottevanger, Toon Van Gorp, Carlos E. Paiva, Judith R. Kroep, Yong-Man Kim, Hee-Seung Kim, Jae-Kwan Lee, Hannelore Denys, Roy Lalisang, Andreia Cristina De Melo, Andres Redondo, Anna K. L. Reyners, Paulo Mora, Celine Closset, Cornelis J. M. Melief, Leon HooftmanShaheda Jamil, Lisa Boersm, Suk-Young Yoo, Frank Seebach, Israel Lowy, Matthew G. Fury, Melissa Mathias, Nicoletta Colombo

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Objective. To estimate the clinical benefit of cemiplimab+peltopepimut-S vaccine after disease progression on first-line chemotherapy. Methods. This global phase 2 open-label study (NCT04646005) recruited patients with recurrent HPV16+ cervical cancer who had previously experienced disease progression after first-line chemotherapy. Patients received a total of 3 doses of peltopepimut-S vaccine on days 1, 29, and 50 and cemiplimab 350 mg every 3 weeks until disease progression or other reason for early discontinuation. Primary endpoint was objective response rate (ORR) per RECISTversion 1.1; secondary endpoints were duration of response (DOR), overall survival (OS), progression-free survival (PFS), and safety. Results. Of 113 patients enrolled between June 28, 2021 and May 22, 2023, 80.5 % were white, with a median age of 49.0 years, and 58.4 % had an ECOG PS of 0. Median duration of follow-up was 4.9 months. ORR (95 % CI) per investigator assessment was 16.8 % (9.9-23.7). ORR of patients with squamous cell carcinoma by PD-L1 expression in tumor cells was 15.8 % for patients with PD-L1 < 1 % and 24.1 % for patients with PD-L1 >= 1 %. Median (95 % CI) DOR was 5.6 (3.5-not estimable) months. Median (95 % CI) OS and PFS were 13.3 (10.8-16.3) months and 3.0 (1.7-4.0) months, respectively. Treatment-emergent adverse events (TEAEs) occurred in 92.9 % of patients, the most common being injection-site reaction (38.9 %) and anemia (25.7 %). Six (5.3 %) patients died from a TEAE. Conclusion. Cemiplimab+peltopepimut-S vaccine provides similar benefits to cemiplimab monotherapy; patients with higher PD-L1 expression in tumor cells may be more likely to benefit from treatment. (c) 2025 Published by Elsevier Inc.
Original languageEnglish
Pages (from-to)28-35
Number of pages8
JournalGynecologic Oncology
Volume196
DOIs
Publication statusPublished - 1 May 2025

Keywords

  • Cemiplimab
  • Recurrent/metastatic
  • Cervical cancer
  • Peltopepimut-S vaccine
  • HPV16
  • SURVIVAL

Fingerprint

Dive into the research topics of 'Cemiplimab plus peltopepimut-S vaccine in recurrent cervical cancer: A phase 2 clinical trial'. Together they form a unique fingerprint.

Cite this